E-Learning

Cero Therapeutics to effect 1-for-100 reverse stock split

CERo Therapeutics (CERO) announced that its board of directors has determined to effect a one-for-one hundred reverse stock split of the Company’s common stock, par value $0.0001 per share. The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 8, 2025, and the Company’s Common Stock will begin trading on a split-adjusted basis on The Nasdaq Global Market as of the opening of trading on January 8, 2025. The CUSIP number of 71902K303 will be assigned to the Company’s Commo

Read more

Futures flat ahead of economic data, investors keep an eye on Trump's plans

(Reuters) -U.S. stock index futures were trading flat on Tuesday ahead of a set of economic data, with investors looking for any insights on the policies of the incoming Trump administration. Any signs of continued resilience in the economy from the data is likely to push back expectations on the pace of the Federal Reserve's monetary easing cycle this year. Top on the investor radar is the Job Openings and Labor Turnover survey for November and the Institute for Supply Management's data on services activity for December, both due at 10 a.m. ET.

Read more

Aclarion, Inc. Raises Funds Through Stock Offering

Aclarion, Inc. ( (ACON) ) just unveiled an update. Aclarion, Inc. announced the pricing of a registered direct offering of common stock, selling 3,380,276 shares at $0.142 per share to raise approximately $480,000. The proceeds will be used for market development, clinical evidence, product development, quality improvement, and general corporate purposes, with Dawson James Securities acting as the sole placement agent. More about Aclarion, Inc. Aclarion, Inc. is a healthcare technology company t

Read more

Analysis-Trump's SEC pick likely to give Wall Street easier enforcement ride

President-elect Donald Trump's SEC pick voted several times against punishing big companies and was extremely critical of the agency's enforcement process when he was a top official there, according to public records and former SEC attorneys, in a possible glimpse of what is to come under his leadership. Paul Atkins voted against at least 10 enforcement actions punishing individuals and companies, including Citigroup and IBM, according to a Reuters review of Securities and Exchange Commission records from the final years of his 2002-2008 stint as a commissioner. In doing so, he defied his fellow Republican agency chairs.

Read more

Morning Bid: A JOLT of reality for markets

A look at the day ahead in U.S. and global markets by Amanda Cooper. Trading action so far has been dominated by uncertainty over incoming U.S. President Donald Trump's threatened tariffs. But the "will he, won't he" narrative looks likely to take a backseat as a number of key metrics on the labour market start to filter through ahead of Friday's jobs data.

Read more